Dark

Check out our Level2View

NEOS
Neos Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Mar 19, 2021

1.15USD-2.542%(-0.03)15,005,940

Pre-market

0.00USD-100.000%(-1.18)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Mar 19, 2021

07:46AM EDT The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs Benzinga

Mar 18, 2021

06:22AM EDT Why Are Neos Therapeutics, Aytu BioScience Stocks Soaring Today? Benzinga

Mar 12, 2021

09:07AM EST Glass Lewis Recommends Neos Therapeutics Stockholders Vote For Pending Merger With Aytu BioScience RTTNews

09:04AM EST The Neos Therapeutics Board of Directors recommend stockholders vote FOR the transaction in advance of the virtual special meeting scheduled for March18, 2021 at 10:00 a.m. Eastern Time GlobeNewswire Inc

Feb 10, 2021

08:05AM EST Aytu BioScience And Neos Therapeutics Announce Special Meetings Of Stockholders Related To Proposed Merger To Be Held On March 18, 2021 Benzinga

08:00AM EST Record date for each Special Meeting of Stockholders is February 5, 2021 GlobeNewswire Inc

Jan 30, 2021

07:06PM EST Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders PR Newswire

Jan 28, 2021

02:29PM EST SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PR Newswire

11:05AM EST Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: GlobeNewswire Inc

Jan 4, 2021

04:01PM EST Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a pre-recorded presentation as part of the H.C. Wainwright Virtual BioConnect Conference. GlobeNewswire Inc

Dec 30, 2020

04:16PM EST Neos Therapeutics Reports Co Received Letter From Nasdaq Indicating Co Failed To Meet $1 Per-Share Minimum Benzinga

Dec 28, 2020

08:15PM EST SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - PS, PR Newswire

Dec 24, 2020

10:49PM EST Lifshitz Law Firm, P.C. Announces Investigation of AJRD, CATM, EXPC, GNBF, PR Newswire

Dec 19, 2020

04:11PM EST SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following PR Newswire

Dec 16, 2020

09:20PM EST Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Neos Therapeutics, Inc. - NEOS PR Newswire

Dec 12, 2020

08:58AM EST Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: GlobeNewswire Inc

Dec 11, 2020

11:41AM EST Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Neos Therapeutics, Inc. (NASDAQ: NEOS) breached their fiduciary duties or violated the federal securities laws in connection with the companys acquisition by Aytu BioScience, Inc. (NASDAQ: AYTU). GlobeNewswire Inc

10:39AM EST SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation GlobeNewswire Inc

Dec 10, 2020

07:35PM EST ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Neos PR Newswire

04:52PM EST SHAREHOLDER ALERT: WeissLaw LLP Investigates Neos Therapeutics, Inc. PR Newswire

02:35PM EST Mid-Afternoon Market Update: Dow Falls Over 100 Points; Airbnb Shares Spike Higher Benzinga

02:31PM EST Mid-Afternoon Market Update: Dow Falls Over 100 Points; Neos Therapeutics Shares Spike Higher Benzinga

12:21PM EST Mid-Day Market Update: Crude Oil Surges 4%; AquaBounty Technologies Shares Plummet Benzinga

10:31AM EST Neos Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Neos Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - NEOS Business Wire

09:45AM EST Return On Capital Employed Overview: Neos Therapeutics Benzinga

08:28AM EST Aytu BioScience, Neos Therapeutics Enter Definitive Merger Agreement RTTNews

08:00AM EST -- Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15MbeginningFY 2022 GlobeNewswire Inc

07:01AM EST Aytu BioScience And Neos Therapeutics Earlier Announced Definitive Merger Agreement Valued At ~$44.9M; Neos Stockholders Will Be Entitled To Receive 0.1088 Shares Of Common Stock Of Aytu For Each Share Of Neos Common Stock Held Benzinga

Nov 9, 2020

07:20AM EST Neos Therapeutics: Q3 Earnings Insights Benzinga

07:19AM EST Neos Therapeutics Q3 EPS $(0.10) Misses $(0.05) Estimate, Sales $12.54M Miss $15.47M Estimate Benzinga

07:00AM EST Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the third quarter ended September 30, 2020 and provided a business update. GlobeNewswire Inc

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 2, 2020

08:00AM EST Neos Therapeutics to Host Third Quarter 2020 Financial and GlobeNewswire Inc

Oct 1, 2020

05:01PM EDT 4 Sectors Moving Up In Thursday's After-Market Session Benzinga

Sep 9, 2020

08:00AM EDT Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020, at 3:40 p.m. ET. GlobeNewswire Inc

Aug 10, 2020

07:21AM EDT Recap: Neos Therapeutics Q2 Earnings Benzinga

07:15AM EDT Neos Therapeutics Q2 EPS $(0.11) Beats $(0.13) Estimate, Sales $13.11M Beat $12.17M Estimate Benzinga

07:00AM EDT Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the second quarter ended June 30, 2020 and provided a business update. GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 3, 2020

08:00AM EDT Neos Therapeutics to Host Second Quarter 2020 Financial and GlobeNewswire Inc

Share